| Phase 19 trials |
|
Phase 1
|
NCT04576091 |
Jul 2022 → Nov 2024 overdue |
hypopharynx squamous cell carcinoma, laryngeal squamous cell carcinoma, major salivary gland carcinoma, oropharynx squamous cell carcinoma +3 |
National Cancer Institute (NCI) |
Active not recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT05010096 |
Mar 2022 |
bone cancer, high grade malignant neoplasm, metastatic malignant neoplasm |
M.D. Anderson Cancer Center |
Withdrawn
|
No outcome recorded
Stop: Enrollment |
|
Phase 1
|
NCT04514497 |
Oct 2021 → Feb 2025 overdue |
metastatic malignant neoplasm, pancreatic adenocarcinoma, small cell lung carcinoma |
National Cancer Institute (NCI) |
Active not recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT04491942 |
Aug 2021 → Jun 2027 expected |
bile duct carcinoma, carcinoma of esophagus, cervical carcinoma, endometrial carcinoma +11 |
National Cancer Institute (NCI) |
Active not recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT04535401 |
Aug 2021 → Feb 2025 overdue |
colorectal carcinoma, gastric carcinoma, gastroesophageal junction adenocarcinoma |
National Cancer Institute (NCI) |
Active not recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT04616534 |
Jun 2021 → Apr 2025 overdue |
fallopian tube serous adenocarcinoma, ovarian serous adenocarcinoma, pancreatic adenocarcinoma, primary peritoneal serous adenocarcinoma |
National Cancer Institute (NCI) |
Active not recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT04267939 |
Feb 2020 → Dec 2023 |
ovarian cancer |
Bayer |
Terminated
|
No outcome recorded
|
|
Phase 1
|
NCT04095273 |
Sep 2019 → Nov 2022 |
cancer |
Bayer |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT03188965 |
Jul 2017 → Dec 2022 |
mantle cell lymphoma |
Bayer |
Completed
|
No outcome recorded
|
| Phase 1/21 trial |
|
Phase 1/2
|
NCT05071209 |
Dec 2021 → Sep 2024 overdue |
Ewing sarcoma, alveolar rhabdomyosarcoma, lymphoma, refractory malignant neoplasm |
National Cancer Institute (NCI) |
Active not recruiting
|
No outcome recorded
|